Stada Leads Competition To Zytiga In Europe
German Generics Giant Launches Prostate Cancer Treatment Abiraterone In 21 Markets
Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.
You may also be interested in...
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.